Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET

Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify those with r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Huang, Shiliang, Michalek, Joel E., Reardon, David A., Wen, Patrick Y., Floyd, John R., Fox, Peter T., Clarke, Geoffrey D., Jerabek, Paul A., Schmainda, Kathleen M., Muzi, Mark, Hyun, Hyewon, Lee, Eudocia Quant, Brenner, Andrew J.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027395/
https://ncbi.nlm.nih.gov/pubmed/33828310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-84331-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados